Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. Academic Article uri icon

Overview

abstract

  • The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.

publication date

  • March 1, 2022

Research

keywords

  • Leukemia, Myeloid, Acute

Identity

Scopus Document Identifier

  • 85125723561

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-21-2124

PubMed ID

  • 34753779

Additional Document Info

volume

  • 28

issue

  • 5